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Background: This study aims to investigate the association between statin use and all-cancer survival in a prospective cohort of
postmenopausal women, using data from the Women’s Health Initiative Observational Study (WHI-OS) and Clinical Trial (WHI-CT).
Methods: The WHI study enrolled women aged 50–79 years from 1993 to 1998 at 40 US clinical centres. Among 146 326
participants with median 14.6 follow-up years, 23 067 incident cancers and 3152 cancer deaths were observed. Multivariable-
adjusted Cox proportional hazards models were used to investigate the relationship between statin use and cancer survival.
Results: Compared with never-users, current statin use was associated with significantly lower risk of cancer death (hazard ratio
(HR), 0.78; 95% confidence interval (CI), 0.71–0.86, Po0.001) and all-cause mortality (HR, 0.80; 95% CI, 0.74–0.88). Use of other lipid-
lowering medications was also associated with increased cancer survival (P-interaction (int)¼ 0.57). The lower risk of cancer death
was not dependent on statin potency (P-int¼ 0.22), lipophilicity/hydrophilicity (P-int¼ 0.43), type (P-int¼ 0.34) or duration
(P-int¼ 0.33). However, past statin users were not at lower risk of cancer death compared with never-users (HR, 1.06; 95% CI,
0.85–1.33); in addition, statin use was not associated with a reduction of overall cancer incidence despite its effect on survival
(HR, 0.96; 95% CI, 0.92–1.001).
Conclusions: In a cohort of postmenopausal women, regular use of statins or other lipid-lowering medications was associated with
decreased cancer death, regardless of the type, duration, or potency of statin medications used.
Cancer is the second leading cause of death among women in the
United States, with over 270 000 cancer deaths in 2015 (Siegel et al,
2015). The use of 3-hydroxy-3-methyl-glutaryl-CoA reductase
inhibitor medications (‘statins’ or ‘HMG Co-A reductase inhibi-
tors’) for cholesterol reduction has been hypothesised to interfere
with cancer growth and metastasis through multiple mechanisms
(Fenton et al, 1992; Herold et al, 1995; Deberardinis et al, 2008;
Gauthaman et al, 2009; Mannello and Tonti, 2009). Current
literature on statin use and cancer survival has been mixed
(Dale et al, 2006; Cholesterol Treatment Trialists’ (CTT)
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Table 1. Participants’ characteristics in the Women’s Health Initiative Clinical Trial and Observational Study by statin use (current
vs never)a at time of cancer diagnosis (N¼17285b)
Current statin use (N¼4025) Never used statins (N¼13260)
N % N % P-valuec
Age at screening (years) o0.001
50–59 1123 27.9 3973 30.0
60–69 2089 51.9 6228 47.0
70–79 813 20.2 3059 23.1
Age at incident cancer o0.001
o70 1338 33.2 6706 50.6
70 to o80 2030 50.4 5295 39.9
X80 657 16.3 1259 9.5
Tumour stage 0.001
In situ 613 15.9 1732 13.8
Local 1924 49.8 6203 49.4
Regional 702 18.2 2552 20.3
Distant 623 16.1 2079 16.5
Race/ethnicity 0.15
White 3517 87.4 11 701 88.2
Black 261 6.5 832 6.3
Hispanic 86 2.1 310 2.3
American Indian 16 0.4 38 0.3
Asian/Pacific Islander 92 2.3 234 1.8
Unknown 53 1.3 145 1.1
Education o0.001
High school/GED or less 899 22.5 2617 19.9
School after high school 1534 38.3 4812 36.5
College degree or higher 1570 39.2 5746 43.6
BMI, baseline (kgm 2) o0.001
o25 1065 26.7 4745 36.1
25 to o30 1474 37.0 4468 33.9
30 to o35 882 22.1 2427 18.4
X35 568 14.2 1522 11.6
Smoking status 0.75
Never 1829 46.0 6115 46.7
Past 1817 45.7 5904 45.1
Current 326 8.2 1074 8.2
Vitamin D intake (IU) 0.97
o200 1418 36.2 4690 36.1
200 to o400 737 18.8 2483 19.1
400 to o600 981 25.0 3229 24.9
X600 784 20.0 2577 19.9
Alcohol intake o0.001
Non/past drinker 1121 28.1 3252 24.7
o1 drink per week 1376 34.5 4367 33.2
1–o7 drinks per week 986 24.7 3656 27.8
X7 drinks per week 511 12.8 1890 14.4
Physical activity (MET—min) 0.03
o100 824 21.7 2683 21.6
100 to o500 1127 29.7 3420 27.5
500 to o1200 1081 28.4 3620 29.1
X1200 768 20.2 2709 21.8
Has current health-care provider 3845 96.1 12 401 94.3 o0.001
Mammogram within last 2 years 3465 88.1 10 822 84.1 o0.001
Hysterectomy at randomisation 1526 37.9 4702 35.5 0.005
Unopposed oestrogen use status 0.64
Never used 2668 66.4 8752 66.1
Past user 509 12.7 1752 13.2
Current user 843 21.0 2746 20.7
Oestrogenþprogesterone use status o0.001
Never used 2934 72.9 9166 69.2
Past user 340 8.5 1123 8.5
Current user 748 18.6 2964 22.4
Age at menarche 0.31
o12 894 22.3 2900 22.0
12–13 2262 56.4 7336 55.6
X14 856 21.3 2970 22.5
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Collaborators et al, 2012; Murtola et al, 2014; Cardwell et al,
2015; Desai et al, 2015; Wu et al, 2015; Zhong et al, 2015),
although a retrospective nationwide Danish study found a
statistically significant 15% reduction in all-cancer mortality
among patients who used statins before cancer diagnosis
(Nielsen et al, 2012).
Given the widespread and rapidly growing statin use in the
United States (Stone et al, 2014), we aimed to investigate the
relationship between statin use and all-cancer survival in the
Women’s Health Initiative (WHI). To our best knowledge, this is
the first prospective study to investigate statins and all-cancer
survival.
MATERIALS AND METHODS
Design, setting, and participants. The WHI is a large, multi-
centre study designed to study major causes of morbidity and
mortality in postmenopausal women. The WHI includes a clinical
trial (CT) and an observational study (OS) cohort, with details
described previously (Hays et al, 2003). Women meeting eligibility
criteria (age 50–79, postmenopausal, minimum life expectancy 3
years) were recruited at 40 US clinical centres between 1 September
1993 and 31 December 1998. Primary analyses focused on current
statin users among the N¼ 23 067 women who experienced an
incident cancer during follow-up (Supplementary Figure 1).
Exposures, confounders, and classification of cases. WHI
implementation details have been previously published (Anderson
et al, 2003). The medication inventory was repeated at years 1, 3,
6, and 9 for the CT, and year 3 for the OS during the initial study
period, which ended on 31 March 2005. The overall follow-up
period for the study was through 20 September 2013. Cancers
were initially verified at the local clinical centre, and then
confirmed by centrally trained physician adjudicators (Curb
et al, 2003).
Statistical analysis. Multivariable-adjusted Cox regression tech-
niques were used to estimate hazard ratios (HRs) and 95%
confidence intervals (CIs) by modelling two-ordered events: time
from enrolment to incident cancer (secondary end point) and
time from incident cancer to cancer death (primary end point).
Statin use was modelled as a time-dependent categorical variable
(Therneau and Grambsch, 2000), with the following levels: (0)
never use, (1) current use (at the time of the latest medication
inventory), (2) past use, and (3) out-of-date medication
inventory (Gong et al, 2016). The primary analysis compared
Table 1. ( Continued )
Current statin use (N¼4025) Never used statins (N¼13260)
N % N % P-valuec
Oral contraceptive use ever 1672 41.5 5451 41.1 0.63
CHD before cancer diagnosis 680 17.0 756 5.7 o0.001
Diabetes before cancer diagnosis 725 18.0 865 6.5 o0.001
Family history of cancer 2639 68.4 8888 69.8 0.12
Aspirin use 1136 28.2 2573 19.4 o0.001
NSAIDs 1684 41.8 4478 33.8 o0.001
DM trial 0.03
Comparison 1011 62.8 2985 59.6
Intervention 600 37.2 2020 40.4
CEEþMPA trial 0.007
Comparison 283 52.7 819 46.1
Intervention 254 47.3 957 53.9
CEE trial 0.04
Comparison 179 56.5 423 49.6
Intervention 138 43.5 430 50.4
CaD trial 0.15
Comparison 638 53.1 1856 50.7
Intervention 563 46.9 1803 49.3
Clinical trial participant 2218 55.1 6830 51.5 o0.001
Mean (s.d.) Mean (s.d.) P-value
Age (years) 63.6 (6.5) 63.7 (7.0) 0.37
Fruit and vegetable consumptiond 4.0 (4.0) 4.1 (2.1) 0.004
Red meat consumptiond 0.7 (0.5) 0.7 (0.6) 0.27
General health (0 worst–100 best) 73.6 (17.2) 75.9 (16.7) o0.001
Abbrviations: BMI¼body mass index; CaD¼ calcium + Vitamin D; CEE¼ conjugated equine estrogen; CHD¼ coronary heart disease; DM¼dietary Modification; GED¼general education
development; MET¼metabolic equivalent; MPA¼medroxyprogesterone acetate; NSAID¼nonsteroidal anti-inflammatory drugs.
aStatin (current vs never) were the exposure groups of interest for the primary analysis.
bAt the time of incident cancer, 23 067 participants were at risk for death and included in the primary analyses. Of these, 4025 participants were currently taking statins; 13 260 participants never
used statins; 397 participants had reported using statins at baseline or follow-up, but were not currently taking statins; and 5385 participants had medication inventories that were out of date, so
their follow-up was censored. Exposure groups were modelled as a time-dependent exposure, so a participants’ group status may change during follow-up (e.g., participants with an out-of-
date inventory were allowed to re-enter the model when a current medications inventory was collected).
cOn the basis of w2-test of association for categorical variables and t-test for continuous variables.
dMedium servings per day.
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current (1) vs never used statins (0), to investigate the effect of
regular statin use.
The Cox proportional hazard analyses were adjusted for
potential confounders and included baseline covariates age, race/
ethnicity, education, smoking, body mass index, physical activity,
family history of cancer, current health-care provider, oral
contraception use, prior unopposed oestrogen use, prior oestrogen
plus progestin use, solar irradiance (latitude), prior CHD history,
prior diabetes history, randomisation into the CaD trial, and age at
menarche. Participants who did not die of cancer were censored at
death due to other causes, last contact, or out-of-date medication
collection.
All analyses were conducted using SAS software, version 9.3
(SAS Institute, Cary, NC, USA) and R software version 2.15
(R Foundation for Statistical, Vienna, Austria).
RESULTS
In our analysis, 146 326 participants contributed 1 805 759 person-
years, median (interquartile range, IQR)¼ 14.6 (8.1–16.2) years
of follow-up. A cumulative 24 404 women were diagnosed with
an incident cancer (Supplementary Figure 1). Of this group, 23 067
women had additional follow-up, median (IQR) of 4.8 (1.8–9.4)
years, with 7411 all-cause mortalities: 5837 cancer deaths following
a diagnosis of incident cancer (78.8%), 613 cardiovascular deaths
(8.3%), and 961 other causes (12.9%). After censoring the follow-
up of women with out-of-date medication inventories, 3152 cancer
deaths were included in the primary analysis of current vs never
statin users (709 current statin users and 2443 non-users). Table 1,
and Supplementary Tables 1 and 2 display baseline characteristics.
Statin group N (%*) HR (95%Cl)
1.00
1.00
1.00
1.00
1.00
1.00
0.57∧
0.33‡
0.34†
0.43
0.22
P **
<0.001
0.78 (0.71,0.86)
0.92 (0.74,1.13)
0.72 (0.56,0.92)
0.76 (0.68,0.85)
0.79 (0.71,0.88)
0.72 (0.58,0.89)
0.81 (0.69,0.94)
0.94 (0.65,1.37)
0.91 (0.70,1.17)
0.72 (0.56,0.91)
0.72 (0.62,0.84)
1.25 (0.62,2.52)
0.73 (0.48,1.13)
0.55 (0.18,1.71)
0.65 (0.53,0.80)
0.90 (0.73,1.12)
0.73 (0.59,0.91)
0.82 (0.59,1.15)
0.78 (0.70,0.86)
0.71 (0.52,0.97)
0.70 (0.50,0.98)
0.50 0.67
Favours current Favours never
0.80 1.00 1.25 1.50 2.00
(3.80%)
(2.33%)
(3.80%)
(3.10%)
(2.69%)
(2.17%)
(3.80%)
(2.35%)
(2.21%)
(3.80%)
(2.54%)
(6.06%)
(2.56%)
(2.69%)
(1.98%)
(6.74%)
(1.42%)
(2.28%)
(4.11%)
(2.45%)
(3.29%)
(2.20%)
(2.41%)
(3.84%)
(2.41%)
(2.18%)
(1.50%)
2443
709
2443
112
81
512
2443
598
107
2443
225
34
78
81
253
8
26
4
1403
124
127
112
54
42
50
667
2384
Statin potency
Statin category
Statin type
Current statin use
Current other use
Currently use both
Statin duration (years)
Statin use
Never
Never
Never
Never
Never
Never
Lipophilic
Hydrophilic
Fluvastatin
Lovastatin
Pravastatin
Simvastatin
Cerivastatin
Rosuvastatin
 2 statins
<3
3–<5
5–<10
10
Lipid lowering medications
Atorvastatin
Low
Medium
High
Current
Figure 1. Number of cancer deaths (annualised %) and multivariable-adjusted HR (95% CI) for statin use (current vs never). Annualised
percentages by exposure group (time dependent) were computed by dividing the total number of cancer deaths, by the corresponding
cumulative person-time since cancer diagnosis, for each exposure group. Cox regression models were adjusted for age at baseline, race/ethnicity,
education, smoking, body mass index (BMI), physical activity, family history of cancer, current health-care provider, oral contraception use, prior
unopposed oestrogen use, prior oestrogen plus progestin use, solar irradiance (latitude), prior CHD history, prior diabetes history, randomisation
into the CaD trial, age at menarche, and stratified by age group, study groups (randomisation arms of the HT trials, DM trial, and OS enrolment)
and enrolment in WHI extensions (I/II). *Annualised percentage. **Significance test of the main effect or test of heterogeneity between non-
referent exposure groups. wTest of heterogeneity between atorvastatin, simvastatin, lovastatin, and pravastatin. zAnalysis of statin duration
included only CT participants; at the time of cancer diagnosis, among current statin users (n¼ 2218), 893 (40.3%) used statins o3 years, 539
(24.3%) 3 to o5 years, 593 (26.7%) 5 to o10 years, and 193 (8.7%) 10þ years. Test of heterogeneity based on a 1 degree-of-freedom test for
trend. ^Test of heterogeneity between statin use and other use.
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Current statin use was associated with lower risk of cancer death
compared with never-use (HR, 0.78; 95% CI, 0.71–0.86; Po0.001;
Figure 1), and lower risk of all-cause mortality (HR, 0.80; 95% CI,
0.74–0.88). The lower risk of cancer death associated with statin
use did not depend on statin potency (P-interaction (int)¼ 0.22),
category (P-int¼ 0.43), type (P-int¼ 0.34), or duration (P-
int¼ 0.33). Other lipid-lowering medications, used alone, were
associated with a similar reduction in cancer deaths compared with
monotherapy statin use (P-int¼ 0.57). Prior statin users were not
at lower risk of cancer death compared with never-users (HR, 1.06;
95% CI, 0.85–1.33).
Statin use was associated with a significantly lower risk of
multiple, but not all cancer types (P-int¼ 0.001; Figure 2). With
the exception of current NSAID use (which attenuated the effect of
statins), current statin use was not modified by any other
subgroups (Supplementary Figure 2).
In a secondary analysis on cancer incidence, beginning at
enrolment, statin use was not associated with a reduction of
incident cancer (HR, 0.96; 95% CI, 0.92–1.001; P¼ 0.056).
DISCUSSION
In this prospective cohort study, we found that current statin use
in postmenopausal women with cancer was associated with lower
risk of cancer death. Use of other lipid-lowering medications was
also associated with a lower risk of cancer death; this finding
suggests that a reduction in circulating cholesterol levels may
mediate increased cancer survival. However, a dose–response
relationship was not found, suggesting that results should be
interpreted cautiously. Multiple molecular mechanisms have
been linked to statins and cancer, including the mevalonate
pathway (Fenton et al, 1992; Herold et al, 1995; Deberardinis
et al, 2008; Boudreau et al, 2010), G-proteins (Wong et al, 2002;
Demierre et al, 2005), isoprenoid-mediated suppression (Wong
et al, 2002), the RAF-mitogen-activated protein kinase 1 pathway
(Wu et al, 2004), and anti-angiogenic properties of statins (Weis
et al, 2002).
Comparison with other studies. Our study results are similar to
findings from a retrospective nationwide Danish study, which
found a statistically significant 15% reduction in all-cancer
mortality among patients who used statins before cancer diagnosis
(Nielsen et al, 2012). Our analysis is additionally strengthened by
its prospective format, ethnically heterogeneous population, and
covariate data. In addition, other studies of specific cancers in
women (including breast and uterine) have suggested the
protective effects of statins on cancer mortality and survival
(Murtola et al, 2014; Cardwell et al, 2015; Nevadunsky et al, 2015).
Also, some prospective cohort studies of cardiovascular disease
have found associations between lower cholesterol levels and lower
risk of death from several cancers (Cambien et al, 1980; Kagan
et al, 1981; Keys et al, 1985).
However, several smaller studies and RCTs have found no
significant associations. A meta-analysis of 27 RCTs in the
Cholesterol Treatment Trialists’ (CTT) Collaborators (2015)
database did not find an association with cancer mortality or
incidence; however, the study used the time from randomisation
rather than the time from incident cancer. A meta-analysis of 26
RCTs also found no effect of statin use on cancer incidence or
survival (Dale et al, 2006). These conflicting results suggest the
need for additional prospective studies and larger RCTs,
particularly with cancer survival as the primary outcome.
Favours current Favours never used
Subgroup
Current
statin use
709 (2.33%)
55 (0.18%) 200 (0.31%)
183 (0.28%)
42 (0.10%)
240 (0.37%)
561 (0.87%)
39 (0.06%)
84 (0.13%)
432 (0.67%)
239 (0.37%)
193 (0.30%)
86 (0.13%)
100 (0.16%)
204 (0.32%)
96 (0.15%)
100 (0.16%)
271 (0.42%)
47 (0.15%)
13 (0.07%)
46 (0.15%)
213 (0.70%)
17 (0.06%)
26 (0.09%)
105 (0.35%)
58 (0.19%)
47 (0.15%)
23 (0.08%)
15 (0.05%)
60 (0.20%)
33 (0.11%)
26 (0.09%)
89 (0.29%)
2443 (3.80%) 0.78 (0.71,0.86)
0.60 (0.42,0.85)
0.58 (0.40,0.85)
0.77 (0.37,1.61)
0.57 (0.40,0.80)
1.17 (0.97,1.40)
0.95 (0.46,1.97)
0.79 (0.47,1.34)
0.68 (0.53,0.87)
0.61 (0.44,0.86)
0.77 (0.54,1.09)
0.88 (0.52,1.49)
0.45 (0.25,0.83)
0.80 (0.58,1.11)
0.89 (0.57,1.40)
0.77 (0.48,1.26)
0.73 (0.56,0.96)
Never used
statins HR (95%Cl) P
<0.0001
0.001
Cancer death
Cause of cancer death
Breast cancer
Ovarian cancer
Endometrial cancer∧
Colorectal cancer
Lung cancer
Gynaecologic cancer
Renal/urinary cancer
Digestive cancer
Brain cancer
Bone/connective tissue cancer
Blood cancer
– Pancreas cancer
– Lymphoma (NHL only)
– Leukaemia
Other cancer
– Other digestive cancer
HR (95%Cl)
0.40 0.50 0.67 0.80 1.00 1.25 1.50 2.00
Figure 2. Number of cancer deaths (annualised %) and multivariable-adjusted HR (95% CI) for statin use (current vs never) by cause of cancer
death. Summary statistics are from a Cox regression model, using cause-specific baseline hazard functions, with the covariate adjustments
described above. *Corresponds to a significance test of the main effect, or an 11-df test of heterogeneity for cause of cancer death. To avoid
double counting, test of heterogeneity is between the main causes of death listed and does not include subtypes (i.e., cancer of the pancreas or
other digestive organs, non-Hodgkins lymphoma, and leukaemia). ^Only participants without a baseline hysterectomy were used to compute the
number of cases and annualised rates. There was one endometrial cancer case among the group of no statin use that reported having had a
hysterectomy.
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Cancer incidence has been studied more extensively than
cancer survival in relation to statin use, but results on the
subject have been mixed (Bjerre and LeLorier, 2001; Bonovas
et al, 2005; Browning and Martin, 2007; Kuoppala et al, 2008;
Haukka et al, 2010; Jagtap et al, 2012; Simon et al, 2012;
Desai et al, 2013; Singh and Singh, 2013; Tan et al, 2013).
Similarly, biomarker-based studies of statins as candidate
breast cancer chemoprevention agents have shown mixed
results (Higgins et al, 2012; Bjarnadottir et al, 2013; Vinayak
et al, 2013).
Strengths and limitations. The strengths of this study include
its prospective nature, large size and geographic distribution,
adjudication of cancer cases, and detailed information
on confounders and exposures. Limitations of the study include
the fact that medication use was not continuously updated,
observational format, and majority Caucasian participants.
The study may not be generalisable to populations other
than postmenopausal women with similar age at cancer
diagnosis. Residual confounding or reverse causation bias
may be present.
Healthy user bias due to socioeconomic factors may also present
in this analysis; however, this should be reduced as WHI data allow
for rich covariate adjustment. In addition, the effect of statin use
on cancer survival remained significant even with sensitivity
analyses including tumour stage, physical functioning, and
mammogram use.
CONCLUSIONS
In conclusion, in a prospective cohort of postmenopausal women,
current use of statins and other cholesterol-lowering medications
was associated with increased all-cancer survival, as well as
increased survival of multiple cancer types. These findings, along
with the previous Danish cohort study, suggest that statin use and/
or lower cholesterol levels may have a protective effect on cancer
death. Further research is needed in an RCT format to better
control for healthy user bias and to study cancer as a primary
outcome.
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